title: Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma.
abstract: BACKGROUND
  Detection of circulating malignant cells (CMCs) through a reverse transcriptase-polymerase chain reaction (RT-PCR) assay seems to be a demonstration of systemic disease. We here evaluated the prognostic role of RT-PCR assays in serially-taken peripheral blood samples from patients with malignant melanoma (MM).
  
  
  METHODS
  One hundred forty-nine melanoma patients with disease stage ranging from I to III were consecutively collected in 1997. A multi-marker RT-PCR assay was used on peripheral blood samples obtained at time of diagnosis and every 6 months during the first two years of follow-up (total: 5 samples). Univariate and multivariate analyses were performed after 83 months of median follow-up.
  
  
  RESULTS
  Detection of at least one circulating mRNA marker was considered a signal of the presence of CMC (referred to as PCR-positive assay). A significant correlation was found between the rate of recurrences and the increasing number of PCR-positive assays (P = 0.007). Presence of CMC in a high number (> or =2) of analysed blood samples was significantly correlated with a poor clinical outcome (disease-free survival: P = 0.019; overall survival: P = 0.034). Multivariate analysis revealed that presence of a PCR-positive status does play a role as independent prognostic factors for overall survival in melanoma patients, adding precision to the predictive power of the disease stage.
  
  
  CONCLUSIONS
  Our findings indicated that serial RT-PCR assay may identify a high risk subset of melanoma patients with occult cancer cells constantly detected in blood circulation. Prolonged presence of CMCs seems to act as a surrogate marker of disease progression or a sign of more aggressive disease.
authors.affiliation: Istituto di Chimica Biomolecolare-Consiglio Nazionale Ricerche, Li Punti-Sassari, Italy. gpalmieri@yahoo.com
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Palmieri
authors.forename: Sabrina M R
authors.initials: SM
authors.lastname: Satriano
authors.forename: Mario
authors.initials: M
authors.lastname: Budroni
authors.forename: Antonio
authors.initials: A
authors.lastname: Cossu
authors.forename: Francesco
authors.initials: F
authors.lastname: Tanda
authors.forename: Sergio
authors.initials: S
authors.lastname: Canzanella
authors.forename: Corrado
authors.initials: C
authors.lastname: Caracò
authors.forename: Ester
authors.initials: E
authors.lastname: Simeone
authors.forename: Antonio
authors.initials: A
authors.lastname: Daponte
authors.forename: Nicola
authors.initials: N
authors.lastname: Mozzillo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Comella
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Castello
authors.forename: Paolo A
authors.initials: PA
authors.lastname: Ascierto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012878:Skin Neoplasms / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor